9-ING-41 in Patients With Advanced Cancers
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
创建时间：
2019-01-15
